164. Strahlenther Onkol. 2018 Jul 4. doi: 10.1007/s00066-018-1329-8. [Epub ahead ofprint]Neoadjuvant chemotherapy for breast cancer-background for the indication oflocoregional treatment.Krug D(1)(2), Baumann R(3), Budach W(4), Dunst J(3), Feyer P(5), Fietkau R(6),Haase W(7), Harms W(8), Hehr T(9), Piroth MD(10), Sedlmayer F(11), Souchon R(12),Wenz F(13), Sauer R(6); Breast Cancer Expert Panel of the German Society ofRadiation Oncology (DEGRO).Author information: (1)Department of Radiation Oncology, University Hospital Heidelberg, ImNeuenheimer Feld 400, 69120, Heidelberg, Germany. davidkrug@gmx.de.(2)National Center for Radiation Research in Oncology (NCRO), Heidelberg,Germany. davidkrug@gmx.de.(3)University Hospital Schleswig-Holstein, Kiel, Germany.(4)Department of Radiation Oncology, University Hospital Düsseldorf, Düsseldorf, Germany.(5)Vivantes Hospital Neukölln, Berlin, Germany.(6)University Hospital Erlangen, Erlangen, Germany.(7)Formerly St.-Vincentius-Hospital, Karlsruhe, Germany.(8)St. Claraspital, Basel, Switzerland.(9)Department of Radiation Oncology, Marienhospital Stuttgart, Stuttgart,Germany.(10)HELIOS-Hospital Wuppertal, Witten/Herdecke University, Wuppertal, Germany.(11)Paracelsus Medical University Hospital, Salzburg, Austria.(12)Formerly University Hospital Tuebingen, Tuebingen, Germany.(13)University Hospital Mannheim, Mannheim, Germany.Neoadjuvant chemotherapy (NACT) has been widely adopted into themultidisciplinary management of breast cancer. The prognostic impact of treatmentresponse has been clearly demonstrated. However, the impact of treatment responseon the indication for adjuvant radiotherapy is unclear. This review summarizesimportant implications of NACT and treatment response on the risk of recurrenceand locoregional multidisciplinary management from the standpoint of radiationoncology.DOI: 10.1007/s00066-018-1329-8 PMID: 29974132 